A case of remarkable response to atezolizumab in ALK-translocated metastatic lung adenocarcinoma

The development of resistance to tyrosine kinase inhibitors (TKIs) in metastatic non-small cell lung cancer (NSCLC) with oncogenic driver mutations highlights the challenge in improving the survival of these patients. The standard of care for ALK-rearranged advanced NSCLC refractory to various gener...

Descripción completa

Detalles Bibliográficos
Autores principales: Von, Cheong E, Fuang, Ho Gwo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2021
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8318922/
https://www.ncbi.nlm.nih.gov/pubmed/34336591
http://dx.doi.org/10.1016/j.rmcr.2021.101478

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8318922/
https://www.ncbi.nlm.nih.gov/pubmed/34336591
http://dx.doi.org/10.1016/j.rmcr.2021.101478

Ejemplares similares